Join
Live feed
·
PRReleasevia Quantisnow
Akebia Therapeutics Inc. logo

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

ByQuantisnow·Wall Street's wire, on your screen.
AKBA· Akebia Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKBA (Akebia Therapeutics Inc.) and more on Quantisnow.